Quality Chemical Industries Limited reported record financial performance during its annual shareholders meeting. The pharmaceutical company achieved net profits of Shs 40.7 billion, representing a 22 percent jump from previous results. Revenue remained steady at Shs 267.1 billion while gross profits climbed 18 percent to reach Shs 108.5 billion. Shareholders approved dividend payments of Shs 13.5 per share, more than doubling the prior year distribution of Shs 5.7. Chief Executive Ajay Kumar Pal credited operational improvements and careful financial oversight for these achievements.
The Luzira facility produces 1.4 billion tablets each year, focusing on antiretroviral and antimalarial medications that meet World Health Organization standards. Chairman Emmanuel Katongole emphasized the company's role in fighting HIV and malaria across Uganda. Management secured a USD 36 million financing package to build a second production site. This expansion will boost annual output to 2.4 billion tablets and add tuberculosis treatments plus injectable medicines. Tax contributions rose to Shs 19.8 billion compared with Shs 15.1 billion previously.
The Luzira facility produces 1.4 billion tablets each year, focusing on antiretroviral and antimalarial medications that meet World Health Organization standards. Chairman Emmanuel Katongole emphasized the company's role in fighting HIV and malaria across Uganda. Management secured a USD 36 million financing package to build a second production site. This expansion will boost annual output to 2.4 billion tablets and add tuberculosis treatments plus injectable medicines. Tax contributions rose to Shs 19.8 billion compared with Shs 15.1 billion previously.
